Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003604585 | SCV004561651 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2023-08-09 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with SYNE2-related conditions. This variant is present in population databases (rs760663583, gnomAD 0.02%). This sequence change replaces methionine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 3961 of the SYNE2 protein (p.Met3961Leu). |
Ambry Genetics | RCV004374360 | SCV004958861 | uncertain significance | not specified | 2024-03-07 | criteria provided, single submitter | clinical testing | The c.11881A>C (p.M3961L) alteration is located in exon 60 (coding exon 59) of the SYNE2 gene. This alteration results from a A to C substitution at nucleotide position 11881, causing the methionine (M) at amino acid position 3961 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |